Compare ELVN & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELVN | ROOT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2020 |
| Metric | ELVN | ROOT |
|---|---|---|
| Price | $16.31 | $77.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $41.20 | ★ $125.80 |
| AVG Volume (30 Days) | ★ 735.9K | 281.8K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 3.34 |
| Revenue | N/A | ★ $1,446,800,000.00 |
| Revenue This Year | N/A | $29.96 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ N/A | $22.79 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $13.30 | $68.08 |
| 52 Week High | $25.37 | $181.14 |
| Indicator | ELVN | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 43.76 |
| Support Level | $15.71 | $75.75 |
| Resistance Level | $17.58 | $83.33 |
| Average True Range (ATR) | 1.45 | 3.66 |
| MACD | -0.51 | -0.23 |
| Stochastic Oscillator | 12.58 | 6.27 |
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.